DERMNasdaqPharmaceutical PreparationsFiscal year ends December 31

Journey Medical Corp

Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026

$5.17+0.21 (+4.13%)

Close on Oct 19, 2026

Market cap: $142.14M
P/E (TTM): –
Dividend yield: –

Journey Medical Corp income statement

Annual Quarterly TTM

Millions of USD, except per-share data. Shares in millions.

Line item	FY 2025 2025-12-31	FY 2024 2024-12-31	FY 2023 2023-12-31	FY 2022 2022-12-31	FY 2021 2021-12-31	FY 2020 2020-12-31
Revenue	62	56	79	74	63	45
Cost of Revenue	21	21	23	31	32	15
Gross Profit	41	35	56	43	31	30
Research & Development	0.48	9.86	7.54	11	2.74	–
Selling, General & Admin	44	40	44	59	40	22
Total Costs & Expenses	70	70	81	101	98	37
Operating Income	-8.17	-14	-2.07	-28	-35	7.85
Interest Expense	3.70	2.70	1.70	2.02	7.03	0.70
Other Non-Operating Income	-3.20	-0.93	-1.56	-2.05	-7.48	-0.70
Pretax Income	-11	-15	-3.63	-30	-42	7.15
Income Tax Expense	0.06	0.06	0.22	0.06	1.63	1.87
Net Income incl. Noncontrolling Interests	-11	-15	-3.85	-30	-44	5.28
Net Income	-11	-15	-3.85	-30	-44	5.28
EPS (Basic)(per share)	-0.47	-0.72	-0.21	-1.69	-4.32	0.58
EPS (Diluted)(per share)	-0.47	-0.72	-0.21	-1.69	-4.32	0.49
Shares Outstanding (Basic, Weighted)(shares)	24	20	18	18	10	9.14
Shares Outstanding (Diluted, Weighted)(shares)	24	20	18	18	10	11
EBITDA	–	–	–	–	-35	7.86

Italic numbers are calculated by StockData (for example Q4 = full year − nine months). Per-share data and share counts are adjusted for stock splits. Hover a number for its source; click it to open the filing on SEC.gov. Click a row to chart it.

Ratios

Latest available, balances at Jun 30, 2026

Profitability, TTM

Gross margin: 65.5%
Operating margin: -4.4%
Net margin: -9.0%
Return on equity, FY2025: -44.0%

Financial strength

Current ratio: 1.59
Debt to equity: 0.79
Debt to assets: 25.9%
Cash to current liabilities: 56.0%

Valuation

P/E ratio: –
Price to sales: 2.08
Price to book: 4.43
Dividend yield: –